Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer models
Adam Stewart(Institute of Cancer Research), Udai Banerji(Royal Marsden NHS Foundation Trust)
Cited by 3
Related Papers
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
|Clinical Cancer Research|2014|47
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
|PLoS ONE|2017|16
Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response
|Journal of Proteome Research|2025|1